Bionano Genomics Announces Publication of a New Study Using OGM to Investigate Chromosome Instability during Culture of Induced Pluripotent Stem Cells
July 21 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO), today announced publication
of a study using optical genome mapping (OGM) to investigate
numerical and structural changes to two induced pluripotent stem
cell (iPSC) lines, WTC-11 and Tuba1-GFP, during long-term
culturing. This research provides scientific and practical support
for the use of OGM workflows in regenerative medicine due to OGM’s
ability to detect hundreds of structural variants (SVs), many of
which had not been seen by other cytogenetic methods and which may
impact the genomic integrity of iPSCs.
iPSCs have the potential to provide greater clinical impact to
patients than stem cells while avoiding possible immunological
rejection because they can be derived from the patient being
treated. In order to be used for gene editing, iPSCs must be
created and expanded in culture, opening the possibility for the
accrual of chromosomal variants over time. In the study, published
in Genes, the authors followed two cell lines over 150 days of
continuous culture, or 50 passages, and found significant changes
to the genome in both using OGM. Additionally, hundreds of SVs not
found in the internal control database were also observed in both
cell lines and accumulated over the course of the study,
potentially impacting gene expression and cell survival. The
authors also suggest that, because of the accumulation of
chromosome changes over time and the unknown effects on iPSCs in
therapy, culture times should be limited.
“Bionano is expanding into markets where OGM is an alternative
workflow for cytogenetics in genetic diseases and cancer. In
addition, we are driving adoption of OGM into the academic research
community to enable novel discoveries connected to structural
variations. This paper outlines the utility of OGM for
pharmaceutical research and drug development, which is a segment of
the genomics market that Bionano is also targeting,” commented Erik
Holmlin, PhD, president and chief executive officer of Bionano
Genomics.
This publication is available at:
https://www.mdpi.com/2073-4425/13/7/1157
About Bionano GenomicsBionano Genomics is a
provider of genome analysis solutions that can enable researchers
and clinicians to reveal answers to challenging questions in
biology and medicine. The Company’s mission is to transform the way
the world sees the genome through OGM solutions, diagnostic
services and software. The Company offers OGM solutions for
applications across basic, translational and clinical research.
Through its Lineagen business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “can” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) convey uncertainty of future events or outcomes
and are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the potential for SVs
to impact iPSCs and the ability for OGM workflows to detect them,
and OGM’s potential value in the pharmaceutical research and drug
development field. Each of these forward-looking statements
involves risks and uncertainties. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
adoption of OGM in new fields, including the pharmaceutical
research and drug development field, the impact of the COVID-19
pandemic on our business and the global economy; general market
conditions; changes in the competitive landscape and the
introduction of competitive technologies or improvements to
existing technologies; failure of future study results to support
those demonstrated in the paper referenced in this press release;
changes in our strategic and commercial plans; our ability to
obtain sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024